Alvarado-Cruz I, Meas R, Paluri S, Carufe K, Khan M, Sweasy J
Mutagenesis. 2019; 35(1):69-78.
PMID: 31880305
PMC: 7016206.
DOI: 10.1093/mutage/gez049.
Garrido F, Ruiz-Cabello F, Aptsiauri N
Cancer Immunol Immunother. 2017; 66(2):259-271.
PMID: 28040849
PMC: 11028748.
DOI: 10.1007/s00262-016-1947-x.
Srivastava P
Cancer Immunol Res. 2015; 3(9):969-77.
PMID: 26342008
PMC: 6722432.
DOI: 10.1158/2326-6066.CIR-15-0134.
Srivastava P, Duan F
Cancer Immunol Immunother. 2013; 62(5):967-74.
PMID: 23604106
PMC: 3634982.
DOI: 10.1007/s00262-013-1422-x.
Dranoff G
Nat Rev Immunol. 2011; 12(1):61-6.
PMID: 22134155
DOI: 10.1038/nri3129.
Multiple vaccinations: friend or foe.
Church S, Jensen S, Twitty C, Bahjat K, Hu H, Urba W
Cancer J. 2011; 17(5):379-96.
PMID: 21952289
PMC: 3614402.
DOI: 10.1097/PPO.0b013e3182346320.
Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism.
Twitty C, Jensen S, Hu H, Fox B
Clin Cancer Res. 2011; 17(20):6467-81.
PMID: 21810919
PMC: 3298078.
DOI: 10.1158/1078-0432.CCR-11-0812.
Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor.
Srivastava N, Srivastava P
PLoS One. 2009; 4(7):e6094.
PMID: 19593447
PMC: 2704956.
DOI: 10.1371/journal.pone.0006094.
Tumor-specific immune responses.
Schreiber H
Semin Immunol. 2008; 20(5):265-6.
PMID: 18977672
PMC: 3644555.
DOI: 10.1016/j.smim.2008.10.001.
Combination antibody-based cancer immunotherapy.
Takeda K, Okumura K, Smyth M
Cancer Sci. 2007; 98(9):1297-302.
PMID: 17559424
PMC: 11159831.
DOI: 10.1111/j.1349-7006.2007.00529.x.
The paradoxical effects of splenectomy on tumor growth.
Prehn R
Theor Biol Med Model. 2006; 3:23.
PMID: 16800890
PMC: 1538594.
DOI: 10.1186/1742-4682-3-23.
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.
Jinushi M, Hodi F, Dranoff G
Proc Natl Acad Sci U S A. 2006; 103(24):9190-5.
PMID: 16754847
PMC: 1482588.
DOI: 10.1073/pnas.0603503103.
On the nature of cancer and why anticancer vaccines don't work.
Prehn R
Cancer Cell Int. 2005; 5(1):25.
PMID: 16060965
PMC: 1185554.
DOI: 10.1186/1475-2867-5-25.
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68.
Dubey P, Hendrickson R, Meredith S, Siegel C, Shabanowitz J, Skipper J
J Exp Med. 1997; 185(4):695-705.
PMID: 9034148
PMC: 2196148.
DOI: 10.1084/jem.185.4.695.
Effect of interleukin 12 on tumor induction by 3-methylcholanthrene.
Noguchi Y, Jungbluth A, Richards E, Old L
Proc Natl Acad Sci U S A. 1996; 93(21):11798-801.
PMID: 8876217
PMC: 38138.
DOI: 10.1073/pnas.93.21.11798.
Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens.
Dudley M, Roopenian D
J Exp Med. 1996; 184(2):441-7.
PMID: 8760797
PMC: 2192736.
DOI: 10.1084/jem.184.2.441.
Heat shock protein 70-associated peptides elicit specific cancer immunity.
Udono H, Srivastava P
J Exp Med. 1993; 178(4):1391-6.
PMID: 8376942
PMC: 2191193.
DOI: 10.1084/jem.178.4.1391.
Heat shock proteins transfer peptides during antigen processing and CTL priming.
Srivastava P, Udono H, Blachere N, Li Z
Immunogenetics. 1994; 39(2):93-8.
PMID: 8276462
DOI: 10.1007/BF00188611.
Cancer antigens: immune recognition of self and altered self.
Houghton A
J Exp Med. 1994; 180(1):1-4.
PMID: 8006576
PMC: 2191545.
DOI: 10.1084/jem.180.1.1.
Role of H-2 antigens in the host response to methylcholanthrene-induced tumors.
Ahrlund-Richter L, Klein E, Merino F
Immunogenetics. 1982; 15(1):53-62.
PMID: 6979509
DOI: 10.1007/BF00375502.
